Pliant Therapeutics to Participate in Upcoming Investor Events
08 February 2024 - 12:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage
biotechnology company and leader in the discovery and development
of novel therapeutics for the treatment of fibrotic diseases, today
announced participation in the following February investor events.
- Oppenheimer 34th Annual
Healthcare Life Sciences Conference Bernard Coulie, M.D.,
Ph.D., Pliant’s President and Chief Executive Officer and Éric
Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in
a fireside chat on Tuesday, February 13, 2024, at 12:00 p.m.
Eastern Time.
- Wells Fargo 2024 West Coast
Biotech Tour Members of Pliant’s senior management will
meet with investors on Wednesday, February 28, 2024, as part of an
invitation-only event hosted by Wells Fargo.
Interested parties may access the live webcast of the
Oppenheimer fireside chat by visiting the Investor Relations’
Events & Presentation page of Pliant’s website. The
webcast replay will be archived on the Pliant website for 30 days
following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical
company and leader in the discovery and development of novel
therapeutics for the treatment of fibrotic diseases. Pliant's lead
product candidate, bexotegrast (PLN-74809), is an oral, small
molecule, dual selective inhibitor of αvß6 and αvß1 integrins that
is in development in the lead indications for the treatment of
idiopathic pulmonary fibrosis, or IPF, and primary sclerosing
cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical-stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social
media X, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From May 2023 to May 2024